Health Alliance
Firma Welfare Instrument
Full Prescribing Info
Betamethasone valerate.
Each 100 g contains: Betamethasone valerate eq. to Betamethasone 0.1 g (0.1% w/w).
Betamethasone valerate is an active topical corticosteroid which produces a rapid response in those inflammatory dermatoses that are normally responsive to topical corticosteroid therapy, and is often effective in the less responsive conditions such as psoriasis.
DERZID Cream is indicated for the treatment of: eczema in children and adults; including atopic and discoid eczemas, prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses, including lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus and they may be used as an adjunct to systemic steroid therapy in generalised erythroderma.
Dosage/Direction for Use
A small quantity of DERZID Cream should be applied to the affected area 2 or 3 times daily until improvement occurs. It may then be possible to maintain improvement by applying once a day, or even less often. If no improvement is seen within 2 to 4 weeks, reassessment of the diagnosis, or referral, may be necessary.
In the more resistant lesions, such as the thickened plaques of psoriasis on elbows and knees, the effect of DERZID Cream can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion is usually adequate to bring about a satisfactory response in such lesions; thereafter, improvement can be maintained by regular application without occlusion.
Rosacea, acne and perioral dermatitis. Primary cutaneous viral infections (e.g. herpes simplex, chickenpox). Hypersensitivity to the preparation.
The use of DERZID Cream is not indicated in the treatment of primarily infected skin lesions caused by infection with fungi (eg candidiasis, tinea), or bacteria (eg impetigo); perianal and genital pruritus; dermatoses in children under 1 year of age, including dermatitis and napkin eruptions.
Adverse Reactions
Prolonged and intensive treatment with highly active corticosteroid preparations may cause local strophic changes in the skin such as striae, thinning, and dilatation of the superficial blood vessels particularly when occlusive dressings are used or when skin folds are involved.
As with other topical corticosteroid, prolonged use of large amounts or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hyperconicism and suppression of the HPA axis. Those effects are likely to occur in infants and children, particularly if occlusive dressings are used. In infants the napkin may act as an occlusive dressing.
In rare instances, treatment of psoriasis with corticosteroids (or its withdrawal) is thought to provoke the pustular form of the disease.
DERZID Cream is usually well tolerated, but if any signs of previously mentioned reactions appear, application should stop immediately.
Store below 30°C and protect from light.
ATC Classification
D07AC01 - betamethasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
Cream 0.1 g (0.1% w/w) x 15 g, 450 g.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in